Clinical trial / 2008
Oral curcumin was well tolerated and showed biological activity in advanced pancreatic cancer
Twenty-five patients with advanced pancreatic cancer received 8 g of oral curcumin daily until progression. Circulating conjugates peaked at 22 to 41 ng/mL, reflecting poor bioavailability. Two of 21 evaluable participants showed biological activity, including one individual with stable disease exceeding 18 months and another with a temporary 73% tumor reduction. Curcumin down-regulated peripheral mononuclear cell expression of NF-kappaB, COX-2, and pSTAT3 without causing toxicities.
- Study type
- Phase II trial
- Who was studied
- 25 patients with advanced pancreatic cancer
- What was measured
- Clinical biological activity and tumor response
THE PAPER
Phase II trial of curcumin in patients with advanced pancreatic cancer.
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Clin Cancer Res, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.